Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD



Status:Recruiting
Conditions:Psychiatric
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - Any
Updated:3/2/2019
Start Date:October 24, 2017
End Date:August 2019
Contact:B

Use our guide to learn which trials are right for you!

An Open-Label, Multi-Site Phase 2 Study of the Safety and Effect of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder

This multi-site, open-label, Phase 2, lead-in study assesses the safety and effect of
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in participants diagnosed
with at least severe posttraumatic stress disorder (PTSD). Therapy teams that have been
identified and trained to work on the sponsor's planned Phase 3 studies will treat at least
one open-label participant in this study. The study will be conducted in up to N=60
participants. A flexible dose of MDMA, followed by a supplemental half-dose unless
contraindicated, is administered during the Treatment Period with manualized psychotherapy in
three open-label monthly Experimental Sessions. This ~12-week Treatment Period is preceded by
three Preparatory Sessions. During the Treatment Period, each Experimental Session is
followed by three Integrative Sessions of non-drug psychotherapy. The Primary Outcome
measure, the change in Clinician Administered PTSD Scale for DSM 5 (CAPS-5) from Baseline.
Exploratory measures will address specific symptoms, or behavior that is sometimes related to
PTSD. Drug safety will be assessed by measuring blood pressure, heart rate and body
temperature during experimental sessions, collecting adverse events and measuring suicidal
thoughts or behaviors with the Columbia Suicide Severity Rating Scale (CSSRS). This study
will compare the effects of three open-label manualized Experimental Sessions of
psychotherapy assisted by flexible doses of MDMA. Initial doses per Experimental Session
include 80 mg or 120 mg of MDMA compounded with lactose, followed 1.5 to 2 hours later by a
supplemental half-dose (40 mg or 60 mg). Total amounts of MDMA to be administered per
Experimental Session range from 80 mg to 180 mg.

PTSD is a serious debilitating disorder that negatively impacts a person's daily life. PTSD
is a stress-related psychiatric condition that may occur following a traumatic event such as
war, disaster, sexual abuse, violence, terrorism, and accidents. PTSD negatively impacts a
person's daily life, resulting in relationship difficulties, difficulty in finding and
maintaining a job, reduced cognitive and psychosocial functioning, substance abuse, high-cost
healthcare use, and increased depression and suicide risk. Available PTSD treatments,
including medications and therapy, effectively treat only a fraction of people who try them
for adequate dose and duration. People with PTSD can be treated with psychotherapies and
pharmacotherapies. In the past decade, there has been a growing amount of research into
medications and other methods that may augment the effectiveness of psychotherapy for PTSD

3,4-methylenedioxymethamphetamine is a drug that releases serotonin, norepinephrine and
dopamine in the brain and indirectly increases levels of the neurohormones oxytocin, arginine
vasopressin and cortisol. The combined neurobiological effects of MDMA increase compassion,
reduce defenses and fear of emotional injury, and enhance communication and introspection.
MDMA produces anxiolytic and prosocial effects, which counteract avoidance and hyperarousal
in the context of therapy. A combined treatment of MDMA and psychotherapy may be especially
useful for treating PTSD.

This multi-site, open-label, Phase 2, lead-in study assesses the safety and effect of
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in participants diagnosed
with at least severe posttraumatic stress disorder (PTSD). Therapy teams that have been
identified and trained to work on the sponsor's planned Phase 3 studies will treat at least
one open-label participant in this study. The study will be conducted in up to N=60
participants. A flexible dose of MDMA, followed by a supplemental half-dose unless
contraindicated, is administered during the Treatment Period with manualized psychotherapy in
three open-label monthly Experimental Sessions. This ~12-week Treatment Period is preceded by
three Preparatory Sessions. During the Treatment Period, each Experimental Session is
followed by three Integrative Sessions of non-drug psychotherapy. The Primary Outcome
measure, the change in Clinician Administered PTSD Scale for DSM 5 (CAPS-5) from Baseline.
Exploratory measures will address specific symptoms or behavior that is sometimes related to
PTSD. Drug safety will be assessed by measuring blood pressure, heart rate and body
temperature during experimental sessions, collecting adverse events and measuring suicidal
thoughts or behaviors with the Columbia Suicide Severity Rating Scale (CSSRS). This study
will compare the effects of three open-label manualized Experimental Sessions of
psychotherapy assisted by flexible doses of MDMA. Initial doses per Experimental Session
include 80 mg or 120 mg of MDMA compounded with lactose, followed 1.5 to 2 hours later by a
supplemental half-dose (40 mg or 60 mg). Total amounts of MDMA to be administered per
Experimental Session range from 80 mg to 180 mg.

Inclusion Criteria:

- Are at least 18 years old

- Are fluent in speaking and reading the predominantly used or recognized language of
the study site

- Agree to have study visits recorded, including Experimental Sessions, Independent
Rater assessments, and non-drug psychotherapy sessions

- Must provide a contact (relative, spouse, close friend or other caregiver) who is
willing and able to be reached by the investigators in the event of a participant
becoming suicidal or unreachable.

Must agree to inform the investigators within 48 hours of any medical conditions and
procedures

- If of childbearing potential, must have a negative pregnancy test at study entry and
prior to each Experimental Session, and must agree to use adequate birth control
through 10 days after the last Experimental Session.

- Must not participate in any other interventional clinical trials during the duration
of the study,

- Must be willing to remain overnight at the study site after each Experimental Session
and be driven home after, and commit to medication dosing, therapy, and study
procedures

- Meet DSM-5 Criteria for Severe PTSD

Exclusion Criteria:

- Are not able to give adequate informed consent

- Have uncontrolled hypertension

- Have a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration
of a QTc interval >450 milliseconds [ms] corrected by Bazett's formula)

- Have a history of additional risk factors for Torsade de pointes (e.g., heart failure,
hypokalemia, family history of Long QT Syndrome)

- Have evidence or history of significant medical disorders

- Have symptomatic liver disease

- Have history of hyponatremia or hyperthermia

- Weigh less than 48 kilograms (kg)

- Are pregnant or nursing, or are of childbearing potential and are not practicing an
effective means of birth control.

- Are abusing illegal drugs
We found this trial at
12
sites
San Francisco, California 94143
Principal Investigator: Josh Woolley, MD, PhD
Phone: 510-985-3522
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Boulder, Colorado 80302
Principal Investigator: Marcela Ot'alora, MA, LPC
Phone: 720-263-0190
?
mi
from
Boulder, CO
Click here to add this to my saved trials
Brookline, Massachusetts 02446
Principal Investigator: Bessel Van der Kolk, MD
Phone: 617-651-2646
?
mi
from
Brookline, MA
Click here to add this to my saved trials
Farmington, Connecticut 06030
Principal Investigator: Monnica Williams, PhD
Phone: 860-679-2631
?
mi
from
Farmington, CT
Click here to add this to my saved trials
2620 East Prospect Road
Fort Collins, Colorado 80525
Principal Investigator: Scott Shannon, MD
Phone: 970-825-6610
?
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Madison, Wisconsin 53706
(608) 263-2400
Principal Investigator: Randy Brown, MD, Ph.D.
Phone: 608-265-8926
University of Wisconsin-Madison In achievement and prestige, the University of Wisconsin-Madison has long been recognized...
?
mi
from
Madison, WI
Click here to add this to my saved trials
1476 Long Grove Drive
Mount Pleasant, South Carolina 29464
Principal Investigator: Yevgeniy Gelfand, MD
Phone: 843-882-5203
?
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
3439 Magazine Street
New Orleans, Louisiana 70123
Principal Investigator: Ray Worthy, MD, Ph.D
Phone: 504-689-6277
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
70 Washington Square S
New York, New York 10012
(212) 998-1212
Principal Investigator: Michael Bogenschutz, MD
Phone: 646-501-4206
New York University More than 175 years ago, Albert Gallatin, the distinguished statesman who served...
?
mi
from
New York, NY
Click here to add this to my saved trials
225 Victory Boulevard
New York, New York 10024
Principal Investigator: Casey Paleos, MD
Phone: 917-830-4948
?
mi
from
New York, NY
Click here to add this to my saved trials
5955 Lankershim Boulevard
North Hollywood, California 91601
Principal Investigator: Cole Marta, MD
Phone: 818-643-5234
?
mi
from
North Hollywood, CA
Click here to add this to my saved trials
San Francisco, California 94114
Principal Investigator: Sylver Quevedo, MD
Phone: 415-400-5722
?
mi
from
San Francisco, CA
Click here to add this to my saved trials